Medimmune Limited

Brian Lobo

Changshou Gao

Scott A Hammond

Claire Louise Dobson

Ronald Herbst

Godfrey Rainey

Darren Schofield

Stacey Drabic

Srinath Kasturirangan

Michelle Morrow

Yariv Mazor

Michael Oberst

Prakash Manikwar

Deborah Goldberg

Simon Dovedi

Jonathan Seaman

Gianluca Carlesso

Kristen Pollizzi

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.

Anti-RSV monoclonal antibody formulation

Growing community of inventors

Gaithersburg, MD, United States of America

Brian Lobo